134 related articles for article (PubMed ID: 29730065)
1. Establishment of the optimal follow-up schedule after radical prostatectomy.
Matsumoto K; Niwa N; Hattori S; Takeda T; Morita S; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Asanuma H; Oya M
Urol Oncol; 2018 Jul; 36(7):341.e9-341.e14. PubMed ID: 29730065
[TBL] [Abstract][Full Text] [Related]
2. External validation of the "optimal PSA follow-up schedule after radical prostatectomy" in a new cohort.
Yanai Y; Matsumoto K; Kosaka T; Takeda T; Tanaka N; Morita S; Mizuno R; Shinojima T; Asanuma H; Oya M
Int J Clin Oncol; 2020 Jul; 25(7):1393-1397. PubMed ID: 32285217
[TBL] [Abstract][Full Text] [Related]
3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
4. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
[TBL] [Abstract][Full Text] [Related]
5. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy.
Niwakawa M; Tobisu K; Fujimoto H; Matsuoka N; Kakizoe T
Int J Urol; 2002 Mar; 9(3):134-40. PubMed ID: 12010322
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
[TBL] [Abstract][Full Text] [Related]
8. The factors predicting biochemical recurrence in patients with radical prostatectomy.
Koca O; Ün S; Türk H; Zorlu F
Arch Ital Urol Androl; 2016 Jan; 87(4):270-5. PubMed ID: 26766796
[TBL] [Abstract][Full Text] [Related]
9. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis.
Leibman BD; Dillioglugil O; Scardino PT; Abbas F; Rogers E; Wolfinger RD; Kattan MW
J Clin Oncol; 1998 Jun; 16(6):2267-71. PubMed ID: 9626230
[TBL] [Abstract][Full Text] [Related]
11. Prostate Specific Antigen Nadir After Radical Cystoprostatectomy in Patients With Benign Prostatic Tissue: A Benchmark To Define Biochemical Recurrence after Radical Prostatectomy.
Hosseini SY; Alemi M; Amini E; Riazi N
Urol J; 2019 Dec; 16(6):563-566. PubMed ID: 31004342
[TBL] [Abstract][Full Text] [Related]
12. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.
Laajala TD; Seikkula H; Seyednasrollah F; Mirtti T; Boström PJ; Elo LL
Sci Rep; 2016 Nov; 6():36161. PubMed ID: 27805011
[TBL] [Abstract][Full Text] [Related]
14. Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Tanaka N; Takeda T; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
World J Urol; 2020 Jul; 38(7):1749-1756. PubMed ID: 31559475
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
17. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
[TBL] [Abstract][Full Text] [Related]
19. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
[TBL] [Abstract][Full Text] [Related]
20. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
